AdobeStock_335029203

PHE/DH/DWP guideline

PHE COVID-19 infection prevention and control guidance

2020-09-08T17:10:00+01:00By

Summary of the latest UK guidance on infection prevention and control measures for COVID-19.

AdobeStock_292279272

NICE guideline

COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response

2020-08-25T13:28:00+01:00By

The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID-19 pandemic.

AdobeStock_340703775

PHE/DH/DWP guideline

PHE guideline on management of exposure to COVID-19

2020-08-20T09:43:00+01:00By

This summary provides guidance on the management of staff and patients in health and social care settings according to exposures, symptoms, and test results.

Pills + magnifying glass

NHS guideline

NHS guidance on NSAIDs in COVID-19

2020-06-26T12:57:00+01:00By NHS England

This summary sets out the clinical policy for the acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19.

Streptococcus pneumoniae or pneumococcus bacterias_AS

PHE/DH/DWP guideline

PHE pneumococcal vaccination guideline (Green Book chapter 25)

2020-06-10T08:29:00+01:00By

A succinct summary of Public Health England’s Green Book chapter 25 pneumococcal vaccination programme

red blood cells

Independent professional body guideline

Recognition and management of sepsis in general practice

2020-06-04T13:44:00+01:00By The UK Sepsis Trust

This Guidelines summary combines recommendations from The UK Sepsis Trust to give guidance on the recognition and management of sepsis in adults, children, and young people over 12 years of age

AdobeStock_162937550

NICE guideline

COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders

2020-05-22T00:44:00+01:00By

The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources

AdobeStock_287082164

NICE guideline

COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response

2020-05-01T14:42:00+01:00By

The purpose of this Guidelines summary is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. 

AdobeStock_331083828

NICE guideline

COVID-19 rapid guideline: managing COVID-19 symptoms in the community

2020-05-01T00:00:00+01:00By

The purpose of this guideline is to provide recommendations for managing COVID‑19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection

Pneumonia

NICE guideline

COVID-19 rapid guideline: pneumonia in adults

2020-04-27T00:11:00+01:00By

The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic.

Resource hub

  • PSNC Seasonal flu service specification

  • COVID-19 rapid guideline: dialysis service delivery

  • PHE COVID-19 infection prevention and control guidance

  • NHS England COVID-19 community pharmacy guideline

  • NHS video consulting guideline

  • COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response

  • PHE guideline on management of exposure to COVID-19

  • General practice in the context of coronavirus (COVID-19)

  • PHE whooping cough vaccination in pregnancy guideline

  • NHS guidance on NSAIDs in COVID-19